155 related articles for article (PubMed ID: 18630476)
21. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
22. [A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer].
Kaern J; Tropé C; Kjørstad KE; Nordal R; Sundfør K; Vergote I; Vossli S; Abeler V; Sandvei R
Tidsskr Nor Laegeforen; 1990 Sep; 110(21):2759-62. PubMed ID: 2219049
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
Mannel RS; Blessing JA; Boike G
Gynecol Oncol; 2000 Oct; 79(1):64-6. PubMed ID: 11006033
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
25. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
26. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
[TBL] [Abstract][Full Text] [Related]
28. The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience.
Jonak C; Raderer M; Zacherl J; Prager G; Troch M; Ba-Ssalamah A; Hejna M
Anticancer Res; 2008; 28(6B):4101-4. PubMed ID: 19192667
[TBL] [Abstract][Full Text] [Related]
29. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
[TBL] [Abstract][Full Text] [Related]
30. [Cisplatin, 5-fluorouracil, and high-dose leucovorin for advanced esophageal cancer].
Yamada R; Yamamoto Y; Morinaga S; Noguchi Y; Yoshida S; Matsumoto A
Gan To Kagaku Ryoho; 2003 Jan; 30(1):59-63. PubMed ID: 12557706
[TBL] [Abstract][Full Text] [Related]
31. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Li M; Zhang J; Wang D; Zhong B; Tucker S; Lu C; Cheng J; Cao C; Xu J; Xu J; Pan H
Anticancer Drugs; 2009 Nov; 20(10):941-5. PubMed ID: 19745719
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Cao W; Yang W; Lou G; Jiang J; Geng M; Xi W; Li H; Ma T; Jin Y
Anticancer Drugs; 2009 Apr; 20(4):287-93. PubMed ID: 19177020
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Im CK; Jeung HC; Rha SY; Yoo NC; Noh SH; Roh JK; Chung HC
Cancer Chemother Pharmacol; 2008 Feb; 61(2):315-21. PubMed ID: 18026677
[TBL] [Abstract][Full Text] [Related]
37. [Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Matsuda T; Ogino K; Hiroyoshi M; Fujita H; Itoh T; Toyama H; Kawai Y; Makita D; Tsunemi K; Moritomo H; Nakamura T
Gan To Kagaku Ryoho; 2006 Jun; 33(6):783-7. PubMed ID: 16770097
[TBL] [Abstract][Full Text] [Related]
38. Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Khoury-Collado F; Bowes RJ; Jhamb N; Aghajanian C; Abu-Rustum NR
Gynecol Oncol; 2007 Jun; 105(3):823-5. PubMed ID: 17363045
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.
Motoyama S; Hamana S; Ku Y; Laoag-Fernandez JB; Deguchi M; Yoshida S; Tominaga M; Iwasaki T; Ohara N; Maruo T
Gynecol Oncol; 2004 Dec; 95(3):576-82. PubMed ID: 15581966
[TBL] [Abstract][Full Text] [Related]
40. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Umesaki N; Izumi R; Fushiki H; Hasegawa K; Kono I; Nishida M; Noguchi H; Okuda H; Sugimori H; Takizawa K; Udagawa Y; Yamamoto K; Tanaka T; Noda K
Gynecol Oncol; 1999 Oct; 75(1):142-4. PubMed ID: 10502441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
